MD2-IN-1
目录号: PL12312 纯度: ≥99%
CAS No. :111797-22-9
商品编号 规格 价格 会员价 是否有货 数量
PL12312-1mg 1mg ¥1285.00 请登录
PL12312-5mg 5mg ¥3616.00 请登录
PL12312-10mg 10mg ¥5786.00 请登录
PL12312-25mg 25mg ¥10447.00 请登录
PL12312-50mg 50mg ¥16876.00 请登录
PL12312-100mg 100mg 询价 询价
PL12312-200mg 200mg 询价 询价
PL12312-10mM*1mLinDMSO 10mM*1mLinDMSO ¥3969.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
MD2-IN-1
英文名称
MD2-IN-1
英文别名
MD2-IN-1;Chalcone, 3,3',4,4',5-pentamethoxy-
Cas No.
111797-22-9
分子式
C20H22O6
分子量
358.39
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
MD2-IN-1 是髓样分化蛋白 2 (MD2) 的抑制剂,对重组人 MD2 (rhMD2) 的 KD 值为 189 μM。
生物活性
MD2-IN-1 is an inhibitor of Myeloid differentiation protein 2 (MD2) with a KD of 189 ?μM for the recombinant human MD2 (rhMD2).
性状
Solid
IC50 & Target[1][2]
KD: 189 μM (rhMD2)
体外研究(In Vitro)
Myeloid differentiation protein 2 (MD2) is a co-receptor of TLR4. Among those derivatives, MD2-IN-1 (compound 20) shows the strongest inhibitory effect on LPS-induced expression of both TNF-α and IL-6. Compare to the vehicle, LPS alone largely increases the amount of TLR4/MD2 complex, while pretreatment with MD2-IN-1 inhibits the increase of TLR4/MD2 complex to the vehicle level. SPR analysis shows that MD2-IN-1 exhibits recognizable binding to rhMD2 protein in a dose-dependent manner, with a KD value of 189?μM, while the KD value of xanthohumol binding to MD2 is 460?μM. Pre-treatment with different doses of MD2-IN-1 dose-dependently reduces FITC-LPS binding to MD2 in cell surface membranes, with a 65% inhibition at 10?μM in terms of mean fluorescence intensity. Pretreatment with MD2-IN-1 also dose-dependently blocks LPS-induced MAPK phosphorylation in the MPMs.
体内研究(In Vivo)
Administration of MD2-IN-1 evidently reduces the LPS-induced increase in protein concentrations in BALF. The lung wet/dry weight ratio is markedly higher in the LPS-treated group than the control group, and MD2-IN-1 treatment reduces LPS-induced pulmonary edema. LPS also causes observable lung histopathologic changes, including areas of inflammatory infiltration, hemorrhage, interstitial edema, thickening of the alveolar wall, and lung tissue destruction. These histopathological changes are ameliorated in the MD2-IN-1 treatment group. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Zhang Y, et al. Discovery of new MD2 inhibitor from chalcone derivatives with anti-inflammatory effects in LPS-induced acute lung injury. Sci Rep. 2016 Apr 27;6:25130.
溶解度数据
In Vitro: DMSO : 50 mg/mL (139.51 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2